Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


OLIENA
Language recovery after stroke
App | Video | PDF (278 pp) | Web

  Lung Cancer

  Free Subscription


04.03.2019

4 Ann Oncol
1 Ann Thorac Surg
1 BMC Cancer
1 Cancer
1 Cancer Cell
1 Cancer Lett
1 Clin Cancer Res
1 Clin Lung Cancer
1 Clin Nucl Med
1 Eur J Cardiothorac Surg
1 Eur Respir J
1 Int J Cancer
2 Int J Radiat Oncol Biol Phys
3 J Cancer Res Clin Oncol
1 J Clin Oncol
1 J Natl Cancer Inst
1 J Nucl Med
1 J Thorac Oncol
1 JAMA Oncol
1 Lancet Oncol
10 Lung Cancer
1 Lung Cancer (Auckl)
2 Mol Carcinog
3 N Engl J Med
18 Oncogene
3 Oncol Rep
2 Oncologist
3 PLoS One
1 Thorax


  Retrieve available abstracts of this week’s articles:
HTML format
Text format
 
 
Single Articles


    Ann Oncol

  1. BLUMENTHAL GM, Gong Y, Kehl K, Mishra-Kalyani P, et al
    Analysis of Time to Treatment Discontinuation of Targeted Therapy, Immunotherapy, and Chemotherapy in clinical trials of patients with non-small cell lung cancer.
    Ann Oncol. 2019 Feb 22. pii: 5362014. doi: 10.1093.
    PubMed     Text format     Abstract available

  2. AMARAL SR, Casal Moura M, Carvalho J, Chaves A, et al
    6PPrognostic significance of neutrophil-to-lymphocyte ratio (NLR) and platelet-to-lymphocyte ratio (PLR) in non-small cell lung cancer (NSCLC) treated with immune checkpoint inhibitors.
    Ann Oncol. 2019;30.
    PubMed     Text format    

  3. WANG M, Ma X
    26PTexture analysis in contrast enhanced CT: New method to predict prognosis of small cell lung cancer treated with platinum-based chemotherapy.
    Ann Oncol. 2019;30.
    PubMed     Text format    

  4. XIE Y
    35PEnhancement of high-LET radiation-induced lung cancer cell apoptosis by Antennapedia proteins (ANTP)-SmacN7.
    Ann Oncol. 2019;30.
    PubMed     Text format    


    Ann Thorac Surg

  5. FLEISHMAN JA
    Tobacco and Lung Cancer: An Addiction to Money.
    Ann Thorac Surg. 2019 Feb 25. pii: S0003-4975(19)30234.
    PubMed     Text format    


    BMC Cancer

  6. SHIRASAWA M, Fukui T, Kusuhara S, Hiyoshi Y, et al
    Efficacy and risk of cytotoxic chemotherapy in extensive disease-small cell lung cancer patients with interstitial pneumonia.
    BMC Cancer. 2019;19:163.
    PubMed     Text format     Abstract available


    Cancer

  7. BLOM EF, Ten Haaf K, Arenberg DA, de Koning HJ, et al
    Treatment capacity required for full-scale implementation of lung cancer screening in the United States.
    Cancer. 2019 Feb 27. doi: 10.1002/cncr.32026.
    PubMed     Text format     Abstract available


    Cancer Cell

  8. MOMCILOVIC M, Bailey ST, Lee JT, Fishbein MC, et al
    The GSK3 Signaling Axis Regulates Adaptive Glutamine Metabolism in Lung Squamous Cell Carcinoma.
    Cancer Cell. 2018;33:905-921.
    PubMed     Text format     Abstract available


    Cancer Lett

  9. LI L, Wang Y, Song G, Zhang X, et al
    HOX cluster-embedded antisense long non-coding RNAs in lung cancer.
    Cancer Lett. 2019 Feb 23. pii: S0304-3835(19)30114.
    PubMed     Text format     Abstract available


    Clin Cancer Res

  10. ZHANG Q, Zhang Y, Chen Y, Qian J, et al
    A novel mTORC1/2 inhibitor (MTI-31) inhibits tumor growth, epithelial-mesenchymal transition, metastases and improves cancer immunity in preclinical lung cancer models.
    Clin Cancer Res. 2019 Feb 22. pii: 1078-0432.CCR-18-2548.
    PubMed     Text format     Abstract available


    Clin Lung Cancer

  11. EZEIFE DA, Morganstein BJ, Lau S, Law JH, et al
    Financial Burden Among Patients With Lung Cancer in a Publically Funded Health Care System.
    Clin Lung Cancer. 2018 Dec 22. pii: S1525-7304(18)30334.
    PubMed     Text format     Abstract available


    Clin Nucl Med

  12. GAWDE S, Singhal A, Kasat A, Parekh S, et al
    Case of Solitary Peritoneal Metastasis From Atypical Bronchopulmonary Carcinoid on 18F-FDG PET/CT.
    Clin Nucl Med. 2019 Jan 4. doi: 10.1097/RLU.0000000000002441.
    PubMed     Text format     Abstract available


    Eur J Cardiothorac Surg

  13. MELEK H, Cetinkaya G, Ozer E, Yenturk E, et al
    Pathological complete response after neoadjuvant/induction treatment: where is its place in the lung cancer staging system?dagger.
    Eur J Cardiothorac Surg. 2019 Feb 26. pii: 5365486. doi: 10.1093.
    PubMed     Text format     Abstract available


    Eur Respir J

  14. CASAL RF, Sepesi B, Sagar AS, Tschirren J, et al
    Centrally-located lung cancer and risk of occult nodal disease: an objective evaluation of multiple definitions of tumor centrality with a dedicated imaging software.
    Eur Respir J. 2019 Feb 28. pii: 13993003.02220-2018.
    PubMed     Text format     Abstract available


    Int J Cancer

  15. SHIN SH, Park HY, Im Y, Jung HA, et al
    Improved Treatment Outcome of Pembrolizumab in Patients with Non-small Cell Lung Cancer and Chronic Obstructive Pulmonary Disease.
    Int J Cancer. 2019 Feb 26. doi: 10.1002/ijc.32235.
    PubMed     Text format     Abstract available


    Int J Radiat Oncol Biol Phys

  16. TRAN PT, Feng F, Ost P
    Live to SABR Another Day?
    Int J Radiat Oncol Biol Phys. 2018;100:1097.
    PubMed     Text format    

  17. PALMA G, Monti S, Xu T, Scifoni E, et al
    Spatial Dose Patterns Associated with Radiation Pneumonitis in a Randomized Trial Comparing Intensity-Modulated Radiation Therapy with Passive Scattering Proton Therapy for Locally Advanced Non-Small Cell Lung Cancer.
    Int J Radiat Oncol Biol Phys. 2019 Feb 26. pii: S0360-3016(19)30274.
    PubMed     Text format     Abstract available


    J Cancer Res Clin Oncol

  18. LIN XR, Zhou XL, Feng Q, Pan XY, et al
    CIK cell-based delivery of recombinant adenovirus KGHV500 carrying the anti-p21Ras scFv gene enhances the anti-tumor effect and safety in lung cancer.
    J Cancer Res Clin Oncol. 2019 Feb 22. pii: 10.1007/s00432-019-02857.
    PubMed     Text format     Abstract available

  19. MIYASHITA T, Omori T, Nakamura H, Sugano M, et al
    Spatiotemporal characteristics of fibroblasts-dependent cancer cell invasion.
    J Cancer Res Clin Oncol. 2019;145:373-381.
    PubMed     Text format     Abstract available

  20. MENG D, Meng M, Luo A, Jing X, et al
    Effects of VEGFR1(+) hematopoietic progenitor cells on pre-metastatic niche formation and in vivo metastasis of breast cancer cells.
    J Cancer Res Clin Oncol. 2019;145:411-427.
    PubMed     Text format     Abstract available


    J Clin Oncol

  21. CAMIDGE DR, Davies KD
    MET Copy Number as a Secondary Driver of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance in EGFR-Mutant Non-Small-Cell Lung Cancer.
    J Clin Oncol. 2019 Feb 27:JCO1900033. doi: 10.1200/JCO.19.00033.
    PubMed     Text format    


    J Natl Cancer Inst

  22. GILL RR, Yeap BY, Bueno R, Richards WG, et al
    Quantitative Clinical Staging for Patients With Malignant Pleural Mesothelioma.
    J Natl Cancer Inst. 2018;110:258-264.
    PubMed     Text format     Abstract available


    J Nucl Med

  23. XING Y, Chand G, Liu C, Cook GJR, et al
    Early phase I study of a (99m)Tc labeled anti-PD-L1 single domain antibody in SPECT/CT assessment of programmed death ligand-1 expression in non-small cell lung cancer.
    J Nucl Med. 2019 Feb 22. pii: jnumed.118.224170. doi: 10.2967/jnumed.118.224170.
    PubMed     Text format     Abstract available


    J Thorac Oncol

  24. CAMIDGE DR, Kim EE, Usari T, Polli A, et al
    Renal Effects of Crizotinib in Patients With ALK-Positive Advanced Non-Small Cell Lung Cancer.
    J Thorac Oncol. 2019 Feb 26. pii: S1556-0864(19)30146.
    PubMed     Text format     Abstract available


    JAMA Oncol

  25. WANG Z, Duan J, Cai S, Han M, et al
    Assessment of Blood Tumor Mutational Burden as a Potential Biomarker for Immunotherapy in Patients With Non-Small Cell Lung Cancer With Use of a Next-Generation Sequencing Cancer Gene Panel.
    JAMA Oncol. 2019 Feb 28. pii: 2726029. doi: 10.1001/jamaoncol.2018.7098.
    PubMed     Text format     Abstract available


    Lancet Oncol

  26. SCHERPEREEL A, Wallyn F, Albelda SM, Munck C, et al
    Novel therapies for malignant pleural mesothelioma.
    Lancet Oncol. 2018;19:e161-e172.
    PubMed     Text format     Abstract available


    Lung Cancer

  27. HEILBRONER SP, Xanthopoulos EP, Buono D, Huang Y, et al
    Impact of estrogen monotherapy on survival in women with stage III-IV non-small cell lung cancer.
    Lung Cancer. 2019;129:8-15.
    PubMed     Text format     Abstract available

  28. ZHENG X, Zhang G, Li P, Zhang M, et al
    Mutation tracking of a patient with EGFR-mutant lung cancer harboring de novo MET amplification: Successful treatment with gefitinib and crizotinib.
    Lung Cancer. 2019;129:72-74.
    PubMed     Text format     Abstract available

  29. ANDRATSCHKE N, Kraft J, Nieder C, Tay R, et al
    Optimal management of brain metastases in oncogenic-driven non-small cell lung cancer (NSCLC).
    Lung Cancer. 2019;129:63-71.
    PubMed     Text format     Abstract available

  30. KOH YW, Lee SJ, Han JH, Haam S, et al
    PD-L1 protein expression in non-small-cell lung cancer and its relationship with the hypoxia-related signaling pathways: A study based on immunohistochemistry and RNA sequencing data.
    Lung Cancer. 2019;129:41-47.
    PubMed     Text format     Abstract available

  31. TUNALI I, Gray JE, Qi J, Abdalah M, et al
    Novel clinical and radiomic predictors of rapid disease progression phenotypes among lung cancer patients treated with immunotherapy: An early report.
    Lung Cancer. 2019;129:75-79.
    PubMed     Text format     Abstract available

  32. GEMINE RE, Ghosal R, Collier G, Parry D, et al
    Longitudinal study to assess impact of smoking at diagnosis and quitting on 1-year survival for people with non-small cell lung cancer.
    Lung Cancer. 2019;129:1-7.
    PubMed     Text format     Abstract available

  33. WATANABE S, Yoshioka H, Sakai H, Hotta K, et al
    Necitumumab plus gemcitabine and cisplatin versus gemcitabine and cisplatin alone as first-line treatment for stage IV squamous non-small cell lung cancer: A phase 1b and randomized, open-label, multicenter, phase 2 trial in Japan.
    Lung Cancer. 2019;129:55-62.
    PubMed     Text format     Abstract available

  34. UBERALL I, Gachechiladze M, Joerger M, Andel J, et al
    Tumor autophagy is associated with survival outcomes in patients with resected non-small cell lung cancer.
    Lung Cancer. 2019;129:85-91.
    PubMed     Text format     Abstract available

  35. MENDOZA DP, Dagogo-Jack I, Chen T, Padole A, et al
    Imaging characteristics of BRAF-mutant non-small cell lung cancer by functional class.
    Lung Cancer. 2019;129:80-84.
    PubMed     Text format     Abstract available

  36. CRINO L, Bronte G, Bidoli P, Cravero P, et al
    Nivolumab and brain metastases in patients with advanced non-squamous non-small cell lung cancer.
    Lung Cancer. 2019;129:35-40.
    PubMed     Text format     Abstract available


    Lung Cancer (Auckl)

  37. BARROWS SM, Wright K, Copley-Merriman C, Kaye JA, et al
    Systematic review of sequencing of ALK inhibitors in ALK-positive non-small-cell lung cancer.
    Lung Cancer (Auckl). 2019;10:11-20.
    PubMed     Text format     Abstract available


    Mol Carcinog

  38. DING Z, Zhu J, Zeng Y, Du W, et al
    The regulation of Neuropilin 1 expression by miR-338-3p promotes non-small cell lung cancer via changes in EGFR signaling.
    Mol Carcinog. 2019 Feb 27. doi: 10.1002/mc.22990.
    PubMed     Text format     Abstract available

  39. BORREGO A, Cabrera WHK, Jensen JR, Correa M, et al
    Germline control of somatic Kras mutations in mouse lung tumors.
    Mol Carcinog. 2018;57:745-751.
    PubMed     Text format     Abstract available


    N Engl J Med

  40. DIKER O
    Atezolizumab plus Chemotherapy in Small-Cell Lung Cancer.
    N Engl J Med. 2019;380:889.
    PubMed     Text format    

  41. HORN L, Liu SV
    Atezolizumab plus Chemotherapy in Small-Cell Lung Cancer. Reply.
    N Engl J Med. 2019;380:889-890.
    PubMed     Text format    

  42. WEISS GJ, Addeo A
    Atezolizumab plus Chemotherapy in Small-Cell Lung Cancer.
    N Engl J Med. 2019;380:888-889.
    PubMed     Text format    


    Oncogene

  43. FANG L, Wu S, Zhu X, Cai J, et al
    MYEOV functions as an amplified competing endogenous RNA in promoting metastasis by activating TGF-beta pathway in NSCLC.
    Oncogene. 2019;38:896-912.
    PubMed     Text format     Abstract available

  44. LIN SC, Chung CH, Chung CH, Kuo MH, et al
    OCT4B mediates hypoxia-induced cancer dissemination.
    Oncogene. 2019;38:1093-1105.
    PubMed     Text format     Abstract available

  45. GLUCK AA, Orlando E, Leiser D, Poliakova M, et al
    Identification of a MET-eIF4G1 translational regulation axis that controls HIF-1alpha levels under hypoxia.
    Oncogene. 2018;37:4181-4196.
    PubMed     Text format     Abstract available

  46. REHRAUER H, Wu L, Blum W, Pecze L, et al
    How asbestos drives the tissue towards tumors: YAP activation, macrophage and mesothelial precursor recruitment, RNA editing, and somatic mutations.
    Oncogene. 2018;37:2645-2659.
    PubMed     Text format     Abstract available

  47. DANKNER M, Rose AAN, Rajkumar S, Siegel PM, et al
    Classifying BRAF alterations in cancer: new rational therapeutic strategies for actionable mutations.
    Oncogene. 2018;37:3183-3199.
    PubMed     Text format     Abstract available

  48. ZHANG H, Wang Y, Dou J, Guo Y, et al
    Acetylation of AGO2 promotes cancer progression by increasing oncogenic miR-19b biogenesis.
    Oncogene. 2019;38:1410-1431.
    PubMed     Text format     Abstract available

  49. DE BOER HR, Pool M, Joosten E, Everts M, et al
    Quantitative proteomics analysis identifies MUC1 as an effect sensor of EGFR inhibition.
    Oncogene. 2019;38:1477-1488.
    PubMed     Text format     Abstract available

  50. YONESAKA K, Takegawa N, Watanabe S, Haratani K, et al
    An HER3-targeting antibody-drug conjugate incorporating a DNA topoisomerase I inhibitor U3-1402 conquers EGFR tyrosine kinase inhibitor-resistant NSCLC.
    Oncogene. 2019;38:1398-1409.
    PubMed     Text format     Abstract available

  51. BOUDRIA A, Abou Faycal C, Jia T, Gout S, et al
    VEGF165b, a splice variant of VEGF-A, promotes lung tumor progression and escape from anti-angiogenic therapies through a beta1 integrin/VEGFR autocrine loop.
    Oncogene. 2019;38:1050-1066.
    PubMed     Text format     Abstract available

  52. LIU L, Yang Y, Liu S, Tao T, et al
    EGF-induced nuclear localization of SHCBP1 activates beta-catenin signaling and promotes cancer progression.
    Oncogene. 2019;38:747-764.
    PubMed     Text format     Abstract available

  53. TESSARI A, Parbhoo K, Pawlikowski M, Fassan M, et al
    RANBP9 affects cancer cells response to genotoxic stress and its overexpression is associated with worse response to platinum in NSCLC patients.
    Oncogene. 2018;37:6463-6476.
    PubMed     Text format     Abstract available

  54. OHNO Y, Shingyoku S, Miyake S, Tanaka A, et al
    Differential regulation of the sphere formation and maintenance of cancer-initiating cells of malignant mesothelioma via CD44 and ALK4 signaling pathways.
    Oncogene. 2018;37:6357-6367.
    PubMed     Text format     Abstract available

  55. BEST SA, Harapas CR, Kersbergen A, Rathi V, et al
    FGFR3-TACC3 is an oncogenic fusion protein in respiratory epithelium.
    Oncogene. 2018;37:6096-6104.
    PubMed     Text format     Abstract available

  56. OOKI A, Dinalankara W, Marchionni L, Tsay JJ, et al
    Epigenetically regulated PAX6 drives cancer cells toward a stem-like state via GLI-SOX2 signaling axis in lung adenocarcinoma.
    Oncogene. 2018;37:5967-5981.
    PubMed     Text format     Abstract available

  57. DI MODUGNO F, Spada S, Palermo B, Visca P, et al
    hMENA isoforms impact NSCLC patient outcome through fibronectin/beta1 integrin axis.
    Oncogene. 2018;37:5605-5617.
    PubMed     Text format     Abstract available

  58. LEE GW, Park JB, Park SY, Seo J, et al
    The E3 ligase C-CBL inhibits cancer cell migration by neddylating the proto-oncogene c-Src.
    Oncogene. 2018;37:5552-5568.
    PubMed     Text format     Abstract available

  59. WANG PS, Chou CH, Lin CH, Yao YC, et al
    A novel long non-coding RNA linc-ZNF469-3 promotes lung metastasis through miR-574-5p-ZEB1 axis in triple negative breast cancer.
    Oncogene. 2018 May 14. pii: 10.1038/s41388-018-0293.
    PubMed     Text format     Abstract available

  60. LAI SC, Phelps CA, Short AM, Dutta SM, et al
    Thyroid transcription factor 1 enhances cellular statin sensitivity via perturbing cholesterol metabolism.
    Oncogene. 2018;37:3290-3300.
    PubMed     Text format     Abstract available


    Oncol Rep

  61. WU Y, Xu M, He R, Xu K, et al
    ARHGAP6 regulates the proliferation, migration and invasion of lung cancer cells.
    Oncol Rep. 2019 Feb 25. doi: 10.3892/or.2019.7031.
    PubMed     Text format     Abstract available

  62. ALCANTARA KMM, Garcia RL
    MicroRNA92a promotes cell proliferation, migration and survival by directly targeting the tumor suppressor gene NF2 in colorectal and lung cancer cells.
    Oncol Rep. 2019 Feb 19. doi: 10.3892/or.2019.7020.
    PubMed     Text format     Abstract available

  63. LIU W, Chen X, He Y, Tian Y, et al
    TNFalpha inhibits xenograft tumor formation by A549 lung cancer cells in nude mice via the HIF1alpha/VASP signaling pathway.
    Oncol Rep. 2019 Feb 21. doi: 10.3892/or.2019.7026.
    PubMed     Text format     Abstract available


    Oncologist

  64. XIA L, Liu Y, Wang Y
    PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Oncologist. 2019;24.
    PubMed     Text format     Abstract available

  65. LU S, Yu Y, Yang Y
    Retrospect and Prospect for Lung Cancer in China: Clinical Advances of Immune Checkpoint Inhibitors.
    Oncologist. 2019;24.
    PubMed     Text format     Abstract available


    PLoS One

  66. SISSUNG TM, Rajan A, Blumenthal GM, Liewehr DJ, et al
    Reproducibility of pharmacogenetics findings for paclitaxel in a heterogeneous population of patients with lung cancer.
    PLoS One. 2019;14:e0212097.
    PubMed     Text format     Abstract available

  67. GUO X, Liu Y, Kim JL, Kim EY, et al
    Effect of cyclical intermittent hypoxia on Ad5CMVCre induced solitary lung cancer progression and spontaneous metastases in the KrasG12D+; p53fl/fl; myristolated p110fl/fl ROSA-gfp mouse.
    PLoS One. 2019;14:e0212930.
    PubMed     Text format     Abstract available

  68. UNRINE JM, Slone SA, Sanderson W, Johnson N, et al
    A case-control study of trace-element status and lung cancer in Appalachian Kentucky.
    PLoS One. 2019;14:e0212340.
    PubMed     Text format     Abstract available


    Thorax

  69. ROGERS TK
    Minimising diagnostic delay in lung cancer.
    Thorax. 2019 Feb 23. pii: thoraxjnl-2018-212927.
    PubMed     Text format    


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: